A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits

Kidney International

Volumn 94, Issue 1, 2018, Pages 199-205

  Gumber, Ramnika ^a   Cohen, Jordana B ^a,b   Palmer, Matthew B ^b   Kobrin, Sidney M ^a   Vogl, Dan T ^c   Wasserstein, Alan G ^a   Nasta, Sunita D ^c   Bleicher, Melissa B ^a   Bloom, Roy D ^a   Dember, Laura ^a,b   Cohen, Adam ^c   Weiss, Brendan M ^c   Hogan, Jonathan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

glomerulonephritis; lymphoma; multiple myeloma; onconephrology

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LAMBDA CHAIN; MYCOPHENOLATE MOFETIL; OFATUMUMAB; PARAPROTEIN; PREDNISONE; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BLACK PERSON; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; ELECTRON MICROSCOPY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HEMATOTHORAX; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; HYPERVOLEMIA; IMMUNOFLUORESCENCE MICROSCOPY; INFUSION RELATED REACTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; NEPHROSCLEROSIS; NONHUMAN; PENNSYLVANIA; PERIPHERAL NEUROPATHY; PLASMA CELL; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN ELECTROPHORESIS; PROTEINURIA; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; VERY ELDERLY; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; FOLLOW UP; GLOMERULUS; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PARAPROTEINEMIA; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOTHERAPY; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PARAPROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85048276289     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2018.02.020     Document Type: Article

References (13)

1. Nasr, S.H., Satoskar, A., Markowitz, G.S., et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 20 (2009), 2055–2064.
2. Bridoux, F., Leung, N., Hutchison, C.A., et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87 (2015), 698–711.
3. Fermand, J.P., Bridoux, F., Kyle, R.A., et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122 (2013), 3583–3590.
4. Bhutani, G., Nasr, S.H., Said, S.M., et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90 (2015), 587–596.
5. Nasr, S.H., Markowitz, G.S., Stokes, M.B., et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 65 (2004), 85–96.
6. Bridoux, F., Javaugue, V., Bender, S., et al. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int 91 (2017), 423–434.
7. Flores-Montero, J., Sanoja-Flores, L., Paiva, B., et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31 (2017), 2094–2103.
8. Mills, J.R., Barnidge, D.R., Dispenzieri, A., et al. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J, 7, 2017, e590.
9. Bonaud, A., Bender, S., Touchard, G., et al. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. Blood 126 (2015), 757–765.
10. Kubiczkova, L., Pour, L., Sedlarikova, L., et al. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 18 (2014), 947–961.
11. Zeniya, M., Mori, T., Yui, N., et al. The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-beta1. Sci Rep, 7, 2017, 13086.
12. Tanday, S., Bortezomib treatment for patients with mantle-cell lymphoma. Lancet Oncol, 16, 2015, e162.
13. Menn-Josephy, H., Lee, C.S., Nolin, A., et al. Renal interstitial fibrosis: an imperfect predictor of kidney disease progression in some patient cohorts. Am J Nephrol 44 (2016), 289–299.